QURE ▲ +6.1% - uniQure N.V. $QURE - uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease 02-NOV-2026 07:05 AM ET